Malinka Jansson

Statistics

Publications

Citations

2.3K

H-Index

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Agilent Technologies (United States)

Bristol-Myers Squibb (United States)

Malinka Jansson is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in immuno-oncology biomarkers, oncology, and immune checkpoint inhibitors.

Publications per year

2016–2018

Publications

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Karina Kulangara, Nancy R. Zhang, Ellie Corigliano et al. · Archives of Pathology & Laboratory Medicine · 2018 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach, Nancy R. Zhang, Ellie Corigliano et al. · Applied immunohistochemistry & molecular morphology · 2016 · 353 citations · Full text

Medicine, Oncology, Pathology +17

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

Marisa Dolled‐Filhart, Charlotte Roach, Grant Toland et al. · Archives of Pathology & Laboratory Medicine · 2016 · 117 citations

Medicine, Oncology, Pathology +17

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma

Thérèse Phillips, Molly M. Millett, Xiaoling Zhang et al. · Applied immunohistochemistry & molecular morphology · 2017 · 34 citations · Full text

Life Sciences, Immunology, Oncology +17

1–5 of 5